company background image
ISCO logo

International Stem Cell OTCPK:ISCO Stock Report

Last Price

US$0.10

Market Cap

US$821.7k

7D

20.0%

1Y

-37.8%

Updated

27 Mar, 2024

Data

Company Financials

International Stem Cell Corporation

OTCPK:ISCO Stock Report

Market Cap: US$821.7k

ISCO Stock Overview

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally.

ISCO fundamental analysis
Snowflake Score
Valuation3/6
Future Growth0/6
Past Performance2/6
Financial Health2/6
Dividends0/6

International Stem Cell Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for International Stem Cell
Historical stock prices
Current Share PriceUS$0.10
52 Week HighUS$0.22
52 Week LowUS$0.046
Beta0.47
1 Month Change26.73%
3 Month Change60.89%
1 Year Change-37.79%
3 Year Change-85.94%
5 Year Change-91.79%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Shareholder Returns

ISCOUS BiotechsUS Market
7D20.0%0.9%0.4%
1Y-37.8%10.3%28.8%

Return vs Industry: ISCO underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ISCO underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ISCO's price volatile compared to industry and market?
ISCO volatility
ISCO Average Weekly Movement60.4%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ISCO's share price has been volatile over the past 3 months.

Volatility Over Time: ISCO's weekly volatility has increased from 43% to 60% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200130Andrey Semechkinhttps://www.internationalstemcell.com

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC- hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson’s disease, as well as for treating stroke and traumatic brain injury. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner.

International Stem Cell Corporation Fundamentals Summary

How do International Stem Cell's earnings and revenue compare to its market cap?
ISCO fundamental statistics
Market capUS$821.65k
Earnings (TTM)US$195.00k
Revenue (TTM)US$8.33m

4.2x

P/E Ratio

0.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISCO income statement (TTM)
RevenueUS$8.33m
Cost of RevenueUS$3.45m
Gross ProfitUS$4.88m
Other ExpensesUS$4.68m
EarningsUS$195.00k

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.024
Gross Margin58.54%
Net Profit Margin2.34%
Debt/Equity Ratio776.4%

How did ISCO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.